« Return to News | Technology Solutions

University of Oklahoma buys biomarker generator

Wednesday, March 2, 2011 01:41 PM

The University of Oklahoma's student newspaper, The Oklahoma Daily, reported the school's college of pharmacy will acquire a biomarker generator from Tennessee-based Advanced Biomarker Technologies (ABT).

The University stated it "will be the first institution in the world to install and use a biomarker generator for help in imaging and diagnosing diseases," according to a report in Fierce Biotech.

ABT's website says the biomarker generator is composed of two technologies: a shielded table-top cyclotron for producing the positron emitting isotopes of C-11 and F-18, plus a flow microchemistry subsystem for labeling specific molecules with the positron emitting isotopes. The system is unique, according to ABT, because it is about 10 times smaller than other PET cyclotrons and is easy to install.

"This is the first, smallest one that has been named as a biomarker generator," Vibhudutta Awasthi, college of pharmacy researcher and professor, told the Oklahoma Daily. "Because of its simplicity, it can produce biomarkers on demand. If a patient is in the clinic and that patient needs an imaging study using a certain biomarker, you can push the button and within 30 to 40 minutes you can have a dose for that patient."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.